Premium
Whole inactivated SIV virion vaccines with functional envelope glycoproteins: safety, immunogenicity, and activity against intrarectal challenge
Author(s) -
Lifson J.D.,
Piatak M.,
Rossio J.L.,
Bess J.,
Chertova E.,
Schneider D.,
Kiser R.,
Coalter V.,
Poore B.,
Imming R.,
Desrosiers R.C.,
Henderson L.E.,
Arthur L.O.
Publication year - 2002
Publication title -
journal of medical primatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.31
H-Index - 42
eISSN - 1600-0684
pISSN - 0047-2565
DOI - 10.1034/j.1600-0684.2002.02007.x
Subject(s) - simian immunodeficiency virus , immunogenicity , virology , immunogen , glycoprotein , adjuvant , biology , immunology , antibody , cd8 , medicine , virus , immune system , monoclonal antibody , microbiology and biotechnology
A novel type of whole inactivated simian immunodeficiency virus (SIV) virion vaccine immunogen with functional envelope glycoproteins was evaluated, without adjuvant, in rhesus macaques. Immunogens included purified inactivated virions of SIVmac239, a designed mutant of SIVmac239 with gp120 carbohydrate attachment sites deleted (SIVmac239 g4,5), and SIVmneE11S. The vaccines were noninfectious, safe, and immunogenic, inducing antibody responses and cellular responses, including responses by CD8+ lymphocytes. Interpretation of protective efficacy following intrarectal challenge was complicated by incomplete take of the challenge in some SIV naïve controls.